Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astellas Pharma Inc (OP: ALPMF ) 11.13 UNCHANGED Last Price Updated: 10:23 AM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Astellas Pharma Inc < Previous 1 2 Next > Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch October 16, 2024 William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... Via Benzinga Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data August 05, 2024 Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... Via Benzinga Bayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval May 17, 2024 Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe menopausal vasomotor symptoms compared to placebo. Via Benzinga Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study October 05, 2023 Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... Via Benzinga Astellas' Menopause Drug Under FDA Review August 18, 2022 Via Benzinga Seagen's Bladder Cancer Trial Data Meets Expectation, Analysts Say July 26, 2022 Via Benzinga Sutro Biopharma Stock Surges On Cancer Treatment Pact June 28, 2022 Via Benzinga Why Is Seagen Stock Trading Higher Today? September 22, 2023 Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: Via Benzinga What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? September 20, 2023 Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected Via Benzinga Why Shares of Adaptive Biotechnologies Jumped This Week June 16, 2023 The company could see its first FDA-approved therapy as early as next year. Via The Motley Fool Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles June 08, 2023 Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as Via Benzinga Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? June 01, 2023 Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? Via News Direct Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold June 27, 2022 Via Benzinga Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? May 30, 2023 The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio Via Benzinga Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories May 15, 2023 Bloomberg Via Benzinga Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback May 15, 2023 The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes Via Benzinga Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% May 01, 2023 Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced Via Benzinga Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' May 01, 2023 Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of Via Benzinga FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer April 04, 2023 Via Benzinga AbbVie Walks Away From CytomX Partnership, But Garnering Attention Of Big Pharma Partners March 28, 2023 Via Benzinga Japanese Government Urges China To Release Astellas Pharma's Employee March 27, 2023 The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities. The reasons why the person was... Via Benzinga Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug March 17, 2023 Via Benzinga Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts January 31, 2023 Via Benzinga Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering January 24, 2023 Via Benzinga Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs October 25, 2022 Via Benzinga Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate July 26, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Seagen Shares Jump On Positive Data From Urothelial Cancer Trial July 26, 2022 Via Benzinga The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives June 28, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies June 27, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies May 09, 2022 Via Benzinga < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
